QA Is Not a Gate — It’s a Technical Partner, with Dr. Andrea Bell

<p>How do biotech companies move QA from late-stage gatekeeper into an early, risk-appropriate technical partner? Dr. Andrea Bell, a VP and Global Head of Quality Assurance, breaks down what phase-appropriate quality looks like across the lifecycle and why the barriers to getting there are cultural rather than procedural.</p><p>Andrea and Nick get into the real cost of late QA involvement, how risk-based rigor differs from uniform rigor, what makes a quality management review actually function, and how QA earns credibility with technical teams.</p><p>A few of Andrea&#39;s key takeaways:</p><ul><li>Late QA involvement costs money <em>and</em> removes the option to remediate cheaply</li><li>Most of the cost of poor quality sits below the waterline in scrap, cycle time, investigations, and reputation</li><li>Early means early in the decision forums, not just early in the lifecycle</li><li>Risk-based rigor isn&#39;t looser rigor. Uniform checklists are a weaker position and agencies will challenge them</li><li>The barriers to embedding QA earlier are quality culture and reporting structure, not procedure</li><li>Data only makes QA proactive if people are empowered to act on it</li><li>QA earns credibility by co-authoring the argument you&#39;ll make to the regulator, not by signing off at the end</li></ul><p><br></p><p><strong>About Andrea Bell</strong></p><p>Andrea Bell is a Vice President and Global Head of Quality Assurance with more than 25 years in biotechnology building quality and CMC organizations across RNA, biologics, and small molecule programs. She holds a doctorate in global public health, a master&#39;s in quality assurance and regulatory affairs, an MBA in international business, and a bachelor&#39;s in biology.</p><p><br></p><p><strong>About The FDA Group</strong></p><p>The FDA Group helps life science organizations rapidly access the industry&#39;s best consultants, contractors, and candidates. Our resources assist in every stage of the product lifecycle, from clinical development to commercialization, with a focus on staff augmentation, auditing, remediation, QMS, and other specialized project work in Quality Assurance, Regulatory Affairs, and Clinical Operations. Learn more: <a href="https://www.thefdagroup.com/" target="_blank" rel="ugc noopener noreferrer">https://www.thefdagroup.com/</a></p>